Back to search results

Utero-ovarian Transposition for Pelvic Cancers

This study is for women aged 18-40 who have pelvic cancers (like colon, rectal, or anal cancer) that need whole pelvic radiation therapy (WPXRT) and who want to protect their ability to have children. The study is testing a procedure called utero-ovarian transposition. This involves temporarily moving your uterus, ovaries, and fallopian tubes outside the area that will receive radiation. After your radiation treatment is finished, a second surgery will return these organs to their normal place. The main goal is to see if this procedure is safe and possible, and if it successfully moves and protects these organs. This study aims to help women preserve their fertility while undergoing cancer treatment.

Study design
This is a Phase I interventional study planning to enroll 26 female participants. It is designed to evaluate the feasibility and safety of utero-ovarian transposition.
What's involved
You would undergo a minimally invasive surgery to move your uterus, ovaries, and fallopian tubes, followed by whole pelvic radiation therapy and/or chemotherapy. After treatment, a second surgery would return these organs to their original position, with monitoring for up to 52 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for success of uterine transposition from enrollment to completion of surveillance at 52 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07419490

Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy

Recruiting
NAAges 18–40InterventionalTreatment
University of South Florida
~26 participants
Updated 2026-06-24 on ClinicalTrials.gov
What's tested:Uteroovarian transposition

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Success of uterine transposition
Measured over From enrollment to completion of surveillance/monitoring at 52 weeks

Conditions

Colorectal (Colon or Rectal) Cancer
Pelvic Malignancies
Oncofertility

Explore related trials

Anal CarcinomaColorectal CarcinomaPelvic Malignancies

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Vaagn Andikyan · PRINCIPAL_INVESTIGATOR · USF Health Morsani College of Medicine

Who to contact

Brittani Powell, MPH, CCRP
[email protected]
(813) 974-5638
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Cardiovascular Disease:
Uncontrolled Diabetes Mellitus:
Severe Respiratory Diseases:
Connective Tissue Disorders:
Severe Inflammatory Bowel Disease (IBD):
Steroid dependency:
FSH: \>10 IU/L
AMH: \<1 ng/mL
Estradiol: outside normal range. 8. Non-Candidate for Fertility: Patients with contraindications to future pregnancy, such as severe uterine abnormalities or significant risk for pregnancy-related complications. 9. Body Mass Index (BMI) ≥35. 10. Absence of One of the Gonadal Vessels. 11. Other unlisted conditions or diagnoses that, in the opinion of the primary investigator, render the patient an unsuitable candidate for uteroovarian transposition.

What this trial measures

  • Success of uterine transpositionFrom enrollment to completion of surveillance/monitoring at 52 weeks

    Success of uterine transposition (feasibility) will be defined as the percentage of cases in which the uterus, ovaries, and fallopian tubes are successfully mobilized and repositioned as planned without the need for intraoperative conversion. Unit of Measure: Percentage of participants (%) Time Frame: up 30 days postsurgery.